← Back to patent-cliff list
VSA-012
Tier C — Watch / tradeVSA-012
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：CFB
Indications (approved)：阵发性血红蛋白尿症, C3肾小球病, 狼疮肾炎, 免疫球蛋白a肾病, 膜增生性肾小球肾炎, Nephropathy
Regional status
US
-
EU
-
China
Phase III
2026-09-04
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of VSA-012?
Approved indications include: 阵发性血红蛋白尿症, C3肾小球病, 狼疮肾炎, 免疫球蛋白a肾病, 膜增生性肾小球肾炎, Nephropathy.
When does the VSA-012 patent expire?
No public expiry year is available for VSA-012 yet; this page updates once verified.
How do I get a quote for VSA-012 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-28